Strategies on the development of small molecule anticancer drugs for targeted therapy

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 611-624

  Lu, Y H ^a   Gao, X Q ^a   Wu, M ^a   Zhang Negrerie, D ^a   Gao, Q ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

Anticancer; Conjugate; Drug design; Drug resistance; Prodrug; Targeted therapy; Transporter

Indexed keywords

7 ALLYLOXY 3 AMINO 1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; ALEMTUZUMAB; ANASTROZOLE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CETUXIMAB; CISPLATIN; CYTOSTATIC AGENT; DENILEUKIN DIFTITOX; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; MONOCLONAL ANTIBODY; OLIGODEOXYRIBONUCLEOTIDE; PACLITAXEL; PANITUMUMAB; RITUXIMAB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; TUMOR ANTIGEN;

ABDOMINAL PAIN; ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CANCER; CAPILLARY LEAK SYNDROME; CARDIAC DYSFUNCTION; CARDIOMYOPATHY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COUGHING; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DIARRHEA; DRUG ACTIVITY; DRUG DESIGN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; DYSPNEA; EDEMA; FATIGUE; FEVER; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEART ARREST; HEART DISEASE; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; IMMUNE RESPONSE; INFECTION; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; METASTASIS; MOUTH DISEASE; MOUTH SORE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PRURITUS; RHINOPHARYNGITIS; RIGOR; SHIVERING; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SWELLING; URTICARIA; VAGINA BLEEDING; VISUAL IMPAIRMENT; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PRODRUGS;

EID: 79960030486     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711795906923     Document Type: Article

References (84)

1. World Health Organization, World Health Statistics, 2009.
2. Quasthoff, S.; Hartung, H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol., 2002, 249, 9-17.
3. Greenblatt, M.; Shubik, P. Tumor Angiogenesis: Trans filter diffusion studies by the transparent chamber technique. J. Natl Cancer Inst., 1968, 41, 111-124.
4. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science, 1987, 235, 442-447.
5. Schellmann, N.; Deckert, P. M.; Bachran, D.; Fuchs, H.; Bachran, C. Targeted enzyme prodrug therapies. Mini Rev. Med. Chem., 2010, 10, 887-904.
6. Witter, D.C; LeBas, J. Cancer as a chronic disease. Oncolog., 2008, 53, 1-3.
7. Maloney, D. G.; Grillo-López, A. J.; White, C. A.; Bodkin, D; Schilder, R. J.; Neidhart, J. A.; Janakiraman, N.; Foon, K. A.; Liles, T. M.; Dallaire, B. K.; Wey, K.; Royston, I.; Davis, T.; Levy, R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 1997, 90, 2188-2195.
8. Scott, S. D. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract., 1998, 6, 195-197.
9. Edwards, J.; Szczepanski, L.; Szechinski, J.; Filipowicz-Sosnowska, A.; Emery, P.; Close, D.; Stevens, R.; Shaw, T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 2572-2581.
10. Bange, J.; Zwick, E.; Ullrich, A. Molecular targets for breast cancer therapy and prevention. Nat. Med. 2001, 7, 548-552.
11. Ménard, S.; Pupa, S. M.; Campiglio, M.; Tagliabue, E. Biologic and therapeutic role of HER2 in cancer. Oncogene, 2003, 22, 6570-6578.
12. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 2000, 6, 443-446.
13. Seidman, A.; Hudis, C.; Pierri, M. K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol., 2002, 20, 1215-1221.
14. Van Cutsem E., Köhne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D'Haens, G.; Pintér, T.; Lim, R.; Bodoky, G.; Roh, JK.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 2009, 360, 1408-1147.
15. Bou-Assaly, W.; Mukherji, S. Cetuximab (erbitux). Am. J. Neuroradiol., 2010, 31, 626-627.
16. Howell, A.; Cuzick, J; Baum M.; Buzdar, A.; Dowsett, M.; Forbes, J. F.; Hoctin-Boes, G.; Houghton, J.; Locker, G. Y.; Tobias, J. S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet., 2005, 365, 60-62.
17. Turturro, F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther., 2007, 7, 11-17.
18. Park, M.; Liu, G. T.; Piltz-Seymour, J.; Wisda, C. L.; Rook, A. H.; Junkins-Hopkins, J. M.; Nasta, S. D.; Kim, E. J. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk. Lymphoma., 2007, 48, 808-811.
19. Bross, P. F.; Beitz, J.; Chen, G.; Chen, X. H.; Duffy, E.; Kieffer, L.; Roy, S.; Sridhara, R.; Rahman, A.; Williams, G; Pazdur, R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res., 2001, 7, 1490-1516.
20. Giles, F. J.; Kantarjian, H. M.; Kornblau, S. M.; Thomas, D. A.; Garcia-Manero, G.; Waddelow, T. A.; David, C. L.; Phan, A. T.; Colburn, D. E.; Rashid, A.; Estey, E. H. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 2001, 92, 406-413.
21. Wadleigh, M.; Richardson, P. G.; Zahrieh, D.; Lee, S. J.; Cutler, C.; Ho, V.; Alyea, E. P.; Antin, J. H.; Stone, R. M.; Soiffer, R. J.; DeAngelo, D. J. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 2003, 102, 1578-1582.
22. Droogendijk, H. J.; Kluin-Nelemans, H. J.; van Doormaal, J. J.; Oranje, A. P.; van de Loosdrecht A. A.; van Daele P. L. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer, 2006, 107, 345-351.
23. Tapper, E.B.; Knowles, D.; Heffron, T.; Lawrence, E.C.; Csete, M. Portopulmonary hypertension: imatinib as a novel treatment and the emory experience with this condition. Transplant. Proc., 2009, 41, 1969-1971.
24. Deininger, M.; Druker, B. J. Specific targeted therapy of chronic myelogenous leukemia with Imatinib. Pharmacol. Rev. 2003, 55, 401-423.
25. Milenic, D. E.; Brady, E. D.; Brechbiel, M. W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug Discov., 2004, 3, 488-499.
26. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 2004, 305, 1163-1167.
27. Mok, T. S.; Wu, Y. L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Eng. J. Med. 2009, 361, 2485-2487.
28. Adams, J.; Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004, 22, 304-311.
29. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. Bortezomibmediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia, 2007, 21, 838-842.
30. Voorhees, P. M.; Dees, E. C.; O'Neil, B.; Orlowski, R. Z. The proteasome as a target for cancer therapy. Clin. Cancer Res. 2003, 9, 6316-6325.
31. Li, Z.; Xu, M.; Xing, S.; Ho, W.; Ishii, T.; Li, Q.; Fu, X.; Zhao, Z. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J. Biol. Chem. 2007, 282, 3428-3432.
32. Thomas, L.; Petty, M. D. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2003, 1, 3-4.
33. Eichholz, A.; Merchant, S.; Gaya, A.M. Anti-angiogenesis therapies: their potential in cancer management. Oncol. Targets Ther. 2010, 3, 69-82.
34. Huang, D.; Ding, Y.; Li, Y.; Luo, W. M.; Zhang, Z. F.; Snider, J.; Vandenbeldt, K.; Qian, C. N. The, B. T. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res., 2010, 70, 1053-1062.
35. Higa, G. M.; Abraham, J. Lapatinib in the treatment of breast cancer (log in required). Expert Rev. Anticancer Ther., (Future Drugs), 2007, 7, 1183-1192.
36. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K.J.; Rusnak, D.W.; Gilmer, T.M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652-6659.
37. Rubio-Viqueira, B.; Hidalgo, M. Targeting mTOR for cancer treatment. Curr. Opin. Investig. Drugs, 2006, 7, 501-512.
38. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I. G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R.J. Temsirolimus, Interferon Alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 2271-2281.
39. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5, 219-234.
40. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu. Rev. Med., 2002, 53, 615-627.
41. Konopleva, M.; Tabe, Y.; Zeng, Z.; Andreeff, M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat., 2009, 12, 103-113.
42. Todaro, M.; Alea, M. P.; Di Stefano, A. B.; Cammareri, P.; Vermeulen, L.; Iovino, F.; Tripodo, C.; Russo, A.; Gulotta, G.; Medema, J.P.; Stassi, G.; Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. CellStem Cell, 2007, 1, 389-402.
43. Wang, Z.; Li, Y.; Banerjee, S.; Sarkar, F. H.; Emerging role of Notch in stem cells and cancer. Cancer Lett., 2009, 279, 8-12.
44. Sarkar, F. H.; Li, Y.; Wang, Z.; Kong, D.; Ali, S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat., 2010, 13, 57-66.
45. Junnotula, V.; Sarkar, U.; Sinha, S.; Gates, K. S. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4- benzotriazine 1,4-dioxide. J. Am. Chem. Soc., 2009, 131, 1015-1024.
46. Ohmichi, M.; Hayakawa, J.; Tasaka, K.; Kurachi, H.; Murata, Y. Mechanisms of platinum drug resistance. Trends Pharmacol. Sci., 2005, 26, 113-116.
47. Oradell, S.; Orenzo, J.; Rovira, A.; van Zutphen, S.; Avile-s, F. X.; Moreno, V.; de Llorens, R.; Martinez, M. A.; Reedijk, J.; Llobet, A. A Water-soluble platinum(II) complexes of diamine chelating ligands bearing amino-acid type substituents: the effect of thelinked amino acid and the diamine chelate ring size on antitumor activity, and interactions with 50-GMP and DNA. J. Inorg. Biochem., 2004, 98, 1933-1946.
48. Sachinvala, N. D.; Chen, H.; Niemczura, W. P.; Furusawa, E.; Cramer, R. E.; Rupp, J. J.; Ganjian, I. Synthesis, characterization, and anticancer activities of the first platinum complexes from sucrose. J. Med. Chem., 1993, 36, 1791-1795.
49. Bloemink, M. J.; Dorenbos, J. P.; Heetebrij, R. J.; Keppler, B. K.; Reedijk, J.; Zahn, H. New antitumor platinum compounds linked to amino phosphonic acids which lose the phosphonate and tertiary amine ligand upon binding to nucleic acids. Inorg. Chem., 1994, 33, 1127-1132.
50. Wingen, F.; Eichmann, T.; Manegold, C.; Krempien, B. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J. Cancer Res. Clin. Oncol., 1986, 111, 35-41.
51. Klenner, T.; Wingen, F.; Keppler, B. K.; Krempien, B.; Schmähl, D. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies. J. Cancer Res. Clin. Oncol., 1990, 116, 341-350.
52. Xue, Z.; Lin, M.; Zhu, J.: Zhang, J.; Li, Y.; Guo, Z. Platinum(II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity. Chem. Commun., 2010, 46, 1212-1214.
53. Ang, W. H.; Khalaila, I.; Allardyce, C. S.; Juillerat-Jeanneret, L.; Dyson, P. J. Rational design of platinum(iv) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc., 2005, 127, 1382-1383.
54. Schultz, M.; Dutta, S.; Tew, K. D. Inhibitors of glutathione Stransferases as therapeutic agents. Adv. Drug Deliver Rev., 1997, 26, 91-104.
55. Morgan, A. S.; Ciaccio, P. J.; Tew, K. D.; Kauvar, L. N. Isozymespecific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother. Pharmacol., 1996, 37, 363-370.
56. Barnes, K. R.; Kutikov, A.; Lippard, S. J. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered latinum (IV) complexes. Chemistry & Biology, 2004, 11, 557-564.
57. Dhar, S.; Lippard, S. J. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc. Natl. Acad. Sci. USA, 2009, 106, 22199-22204.
58. Winquist, R.J.; Furey, B.F.; Bouche, D.M.; Cancer stem cells as the relevant biomass for drug discovery. Current opinion in pharmacology. 2010, 10, 385-390.
59. Singh, A.; Settleman, J. EMT, Cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010, 29, 4741-4751.
60. Brahimi, F.; Matheson, S. L.; Dudouit, F.; McNamee, J. P.; Tari, A. M.; Jean-Claude, B. J. Inhibition of epidermal growth factor receptormediated signaling by "combi-triazene" BJ2000, a new probe forcombi-targeting postulates. J. Pharmacol. Exp. Ther., 2002, 303, 238-246.
61. Matheson, S. L.; McNamee, J.; Jean-Claude, B. J. Design of achimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J. Pharmacol. Exp., 2001, 296, 832-840.
62. Domarkas, J.; Dudouit, F.; Williams, C.; Qiyu, Q.; Banerjee, R.; Brahimi, F.; Jean-Claude, B. J. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the Epidermal Growth Factor Receptor (EGFR). J. Med. Chem., 2006, 49, 3544-3552
63. Katsoulas, A.; Rachid, Z.; McNamee, J. P.; Williams, C.; Jean- Claude, B. J. Combi-targeting concept: an optimized singlemolecule dual-targeting model for the treatment of chronic myelogenous leukemia. Mol. Cancer, 2008, 7, 1033-1043.
64. Katsoulas, A.; Rachid, Z.; Brahimi, F.; McNamee, J.; Jean-Claude, B. J. Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leuk. Res., 2005, 29, 693-700.
65. Katsoulas, A.; Rachid, Z.; Brahimi, F.; McNamee, J.; Jean-Claude, B. J. Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. Leuk. Res., 2005, 29, 565-572.
66. Zunino, F.; Savi, G.; Pasini, A. Synthesis and antitumor activity of a platinum (II)-doxorubicin complex. Cancer Chemother. Pharmacol., 1986, 18, 180-182.
67. Henne, W. A.; Doorneweerd, D. D.; Hilgenbrink, A. R.; Kularatne, S. A.; Low, P. S. Synthesis and activity of a folate peptide camptothecin prodrug. Bioorganic & Med. Chem. Letts., 2006, 16, 5350-5355.
68. Liu, J.; Kolar, C.; Lawson, T. A.; Gmeiner, W. H. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J. Org. Chem., 2001, 66, 5655-5663.
69. Steinberg, G.; Borch, R. F.; Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. J. Med. Chem., 2001, 44, 69-73.
70. Huang, Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev., 2007, 26, 183-201.
71. Airley, R.; Loncaster, J.; Davidson, S.; Bromley, M.; Roberts, S.; Patterson, A.; Hunter, R.; Stratford, I.; West, C. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res., 2001, 7, 928-934.
72. Younes, M.; Brown, R. W.; Stephenson, M.; Gondo, M. Cagle, P. T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer, 1997, 80, 1046-1051.
73. Zamora-León, S. P.; Golde, D. W.; Concha, I. I.; Rivas, C. I.; Delgado-López, F.; Baselga, J.; Nualart, F.; Vera, J. C. Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA, 1996, 93, 1847-1852.
74. Minko, T; Paranjpe P. V.; Qiu, B.; Lalloo, A,; Won, R; Stein, S.; Sinko, P. J. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 2002, 50, 143-150.
75. Chatterjee, N. S.; Kumar, C.K.; Ortiz, A.; Rubin, S. A.; Said, H. M. Molecular mechanism of the intestinal biotin transport process. Am. J. Physiol., 1999, 277, C605-C613.
76. Prasad, P. D.; Wang, H.; Huang, W.; Fei, Y. J.; Leibach, F. H; Devoe, L. D.; Ganapathy V. Arch. Molecular and functional characterization of the intestinal Na+-dependent multivitamin transporter. Biochem.Biophys., 1999, 366, 95-106.
77. Minko, T.; Paranjpe, P. V.; Qiu, B.; Lalloo, A.; Won, R.; Stein, S.; Sinko, P. J. Enhancing the anticancer efficacy of camptothecin using biotinylated poly (ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 2002, 50, 143-150.
78. Mathupala, S. P.; Parajuli, P.; Sloan, A. E. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery, 2004, 55, 1410-1419.
79. Mathupala, S. P.; Colen, C. B.; Parajuli, P.; Sloan, A. E. Lactate and malignant tumors: A therapeutic target at the end stage of glycolysis. J. Bioenerg. Biomembr., 2007, 39, 73-77.
80. Marilyn, E.; Morris; Melanie, A.; Felmlee; Overview of the protoncoupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse γ- hydroxybutyric acid. The AAPS Journal, 2008, 10, 311-321.
81. Halestrap, A. P.; Denton, R. M. Specific inhibition of pyruvate transport in rat liver mitochondria and human erythrocytes by alpha-cyano-4-hydroxycinnamate. Biochem. J., 1974, 138, 313-316.
82. Spencer, T. L.; Lehninger, A. L. L-lactate transport in Ehrlich ascites-tumour cells. Biochem. J. 1976, 154, 405-414.
83. Wahl, M. L.; Owen, J. A.; Burd, R.; Herlands, R. A.; Nogami, S. S.; Rodeck, U.; Berd, D.; Leeper, D. B.; Owen, C. S. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol. Cancer. Ther., 2002, 1, 617-628.
84. Coss, R. A.; Storck, C. W.; Daskalakis, C.; Berd, D.; Wahl.; M. L., Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells. Mol. Cancer. Ther., 2003, 2, 383-388.γ